_1777294237270_124456903.png&w=48&q=75){kind=small}
Novo Nordisk sues Eli Lilly over GLP-1 ads
Novartis has filed a lawsuit against Eli Lilly, alleging that the company has misled consumers about the effectiveness of Lilly's obesity and diabetes medications through advertisements based on old studies, while ignoring new evidence that the high-dose version of Wegovy, launched by Novartis in March, achieves weight loss rates comparable to Lilly's products. Novartis is seeking to prevent Lilly from broadcasting and perpetuating these advertisements, as well as requesting financial compensation. This legal action occurs amid fierce competition for market share in the GLP-1 drug sector, where Lilly's medications are the best-sellers, and Novartis is focusing on its new products, pricing strategies, and dosage adjustments to counter this rivalry.
Notice: This Is an AI-Generated Summary
Comments (0)